There may be metabolic changes taking place during long-term treatment with bone sparing molecules (i.e., such as in the case of parathyroid hormone therapy) to overcome bone homeostasis effects induced by HE [55]. This evidence concerns the gene PTH and hereditary elliptocytosis.